No Data
No Data
No Data
No Data
No Data
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$125m Drop Adds to Long-term Losses
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions The top 11 shareholders own 50% of the company Recent sale
Simply Wall St18:06
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics with a Neutral and maintains $29 price target.
Analyst UpgradesApr 24 01:11
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 31.1% Wedbush → $29 Reiterates Neutral → Neutral 02/23/2024 44.67% Goldman Sachs → $32 Downgrad
BenzingaApr 24 01:10
Intellia Therapeutics Welcomes New Principal Accounting Officer
TipRanksApr 16 04:32
2 Stocks Down 30% to Buy Right Now
Yahoo FinanceApr 14 17:55
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
Yahoo FinanceApr 12 16:50
No Data
No Data